CLCD / CoLucid Pharmaceuticals, Inc. - تصريحات هيئة الأوراق المالية والبورصات، التقرير السنوي، بيان الوكيل

CLCD / CoLucid Pharmaceuticals, Inc. / Novo A/S - SC 13D/A Activist Investment

SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 2)* CoLucid Pharmaceuticals, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 19716T 101 (CUSIP Number) Peter Haahr Novo A/S Tuborg Havnevej 19 Hellerup, Denmark DK-2900 +45 3527 6592 Copy to: B. Shayne K

CoLucid Pharmaceuticals 15-12B

15-12B UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. Commission File Number 001-37358 COLUCID PHARMACEUTICALS, INC. (Exact name of registrant as

CoLucid Pharmaceuticals POST EFFECTIVE AMEND NO 1 TO FORM S-8

POST EFFECTIVE AMEND NO 1 TO FORM S-8 As filed with the Securities and Exchange Commission on March 2, 2017 Registration No.

CoLucid Pharmaceuticals POST EFFECTIVE AMEND NO 1 TO FORM S-8

POST EFFECTIVE AMEND NO 1 TO FORM S-8 As filed with the Securities and Exchange Commission on March 2, 2017 Registration No.

CoLucid Pharmaceuticals POS AM

POS AM As filed with the Securities and Exchange Commission on March 2, 2017 Registration No.

CLCD / CoLucid Pharmaceuticals, Inc. / GAMCO INVESTORS, INC. ET AL Activist Investment

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1) CoLucid Pharmaceuticals, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 19716T101 (CUSIP Number) David Goldman GAMCO Investors, Inc. One Corporate Center Rye, New York 10580-1435 (914) 921-5000 (Name, Address and Telephone

AMENDED AND RESTATED CERTIFICATE OF INCORPORATION COLUCID PHARMACEUTICALS, INC.

EX-3.1 Exhibit 3.1 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF COLUCID PHARMACEUTICALS, INC. 1. The name of the Corporation is: CoLucid Pharmaceuticals, Inc. 2. The address of the Corporation?s registered office in the State of Delaware is Corporation Trust Center, 1209 Orange Street, in the City of Wilmington, County of New Castle, Delaware, 19801. The name of its registered agent at suc

BYLAWS COLUCID PHARMACEUTICALS, INC. TABLE OF CONTENTS

EX-3.2 Exhibit 3.2 BYLAWS OF COLUCID PHARMACEUTICALS, INC. TABLE OF CONTENTS Page ARTICLE I Meetings of Stockholders 1 Section 1.1. Annual Meetings 1 Section 1.2. Special Meetings 1 Section 1.3. Notice of Meeting 1 Section 1.4. Quorum 1 Section 1.5. Adjournments 1 Section 1.6. Voting 2 Section 1.7. Proxies 2 Section 1.8. Judges of Election 2 ARTICLE II Board of Directors 2 Section 2.1. Number 2 Se

Changes in Control of Registrant, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Material Modification to Rights of Security Holders, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits, Completion of Acquisition or Disposition of Assets

8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 1, 2017 COLUCID PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware (State or Other Jurisdiction of Incorporation) 001-37358 (Commission Fi

CoLucid Pharmaceuticals SC 14D9/A

SC 14D9/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 2 to SCHEDULE 14D-9 (Rule 14d-101) Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 COLUCID PHARMACEUTICALS, INC. (Name of Subject Company) COLUCID PHARMACEUTICALS, INC. (Name of Persons Filing Statement) Common Stock, par value $0.001 per share (Title

CoLucid Pharmaceuticals SC TO-T/A

SC TO-T/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 (Amendment No. 2) CoLucid Pharmaceuticals, Inc. (Name of Subject Company (Issuer)) ProCar Acquisition Corporation (Offeror) a wholly-owned subsidiary of Eli Lilly and Company (Parent of Offeror) (Names of Fili

CLCD / CoLucid Pharmaceuticals, Inc. / LILLY ELI & CO - SC 13D/A Activist Investment

SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Amendment No. 1) Under the Securities Exchange Act of 1934 CoLucid Pharmaceuticals, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 19716T101 (CUSIP Number) Copies to: Michael J. Harrington, Esq. General Counsel Eli Lilly and Company Lilly Corporate Center In

CoLucid Pharmaceuticals SC TO-T/A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 (Amendment No. 1) CoLucid Pharmaceuticals, Inc. (Name of Subject Company (Issuer)) ProCar Acquisition Corporation (Offeror) a wholly-owned subsidiary of Eli Lilly and Company (Parent of Offeror) (Names of Filing Persons

CoLucid Pharmaceuticals SC 14D9/A

SC 14D9/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 1 to SCHEDULE 14D-9 (Rule 14d-101) Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 COLUCID PHARMACEUTICALS, INC. (Name of Subject Company) COLUCID PHARMACEUTICALS, INC. (Name of Persons Filing Statement) Common Stock, par value $0.001 per share (Title

CLCD / CoLucid Pharmaceuticals, Inc. / PRICE T ROWE ASSOCIATES INC /MD/ - CLCD AS OF 01/31/2017 Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3) COLUCID PHARMACEUTICALS INC (Name of Issuer) COMMON STOCK (Title of Class of Securities) 19716T101 (CUSIP Number) January 31, 2017 (Date of Event which Requires Filing of Statement) Check the appropriate box to designate the Rule pursuant to which this Sc

CLCD / CoLucid Pharmaceuticals, Inc. / Care Capital III LLC - SC 13G/A Passive Investment

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2 (Amendment No. 1)* CoLucid Pharmaceuticals, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 19716T101 (CUSIP Number) January 26,

CLCD / CoLucid Pharmaceuticals, Inc. / GAMCO INVESTORS, INC. ET AL Activist Investment

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 CoLucid Pharmaceuticals, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 19716T101 (CUSIP Number) David Goldman GAMCO Investors, Inc. One Corporate Center Rye, New York 10580-1435 (914) 921-5000 (Name, Address and Telephone Number of Person

CoLucid Pharmaceuticals SC 14D9

SC 14D9 Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.

Offer to Purchase All Outstanding Shares of Common Stock COLUCID PHARMACEUTICALS, INC. $46.50 PER SHARE, Net in Cash Pursuant to the Offer to Purchase dated January 31, 2017 PROCAR ACQUISITION CORPORATION, a wholly-owned subsidiary ELI LILLY AND COMP

EX-99.(a)(1)(D) Exhibit (a)(1)(D) Offer to Purchase All Outstanding Shares of Common Stock of COLUCID PHARMACEUTICALS, INC. at $46.50 PER SHARE, Net in Cash Pursuant to the Offer to Purchase dated January 31, 2017 by PROCAR ACQUISITION CORPORATION, a wholly-owned subsidiary of ELI LILLY AND COMPANY THE OFFER AND WITHDRAWAL RIGHTS WILL EXPIRE AT ONE MINUTE PAST 11:59 P.M., NEW YORK CITY TIME, ON TU

CoLucid Pharmaceuticals SC TO-T

SC TO-T UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 CoLucid Pharmaceuticals, Inc. (Name of Subject Company (Issuer)) ProCar Acquisition Corporation (Offeror) a wholly-owned subsidiary of Eli Lilly and Company (Parent of Offeror) (Names of Filing Persons) Common S

Notice of Offer to Purchase All Outstanding Shares of Common Stock COLUCID PHARMACEUTICALS, INC. at $46.50 Per Share, Net in Cash PROCAR ACQUISITION CORPORATION, a wholly-owned subsidiary ELI LILLY AND COMPANY

EX-99.(a)(1)(F) Exhibit (a)(1)(F) This announcement is neither an offer to purchase nor a solicitation of an offer to sell Shares (as defined below). The Offer (as defined below) is made only by the Offer to Purchase, dated January 31, 2017, and the related Letter of Transmittal and any amendments or supplements thereto, and is being made to all holders of Shares. The Offer is not being made to (n

September 19, 2016

EX-99.(d)(3) Exhibit (d)(3) September 19, 2016 CONFIDENTIAL Eli Lilly and Company Lilly Corporate Center Indianapolis, Indiana 46285 Ladies and Gentlemen: Your company (referred to as ?you? or ?your,? as appropriate) advised us that you are interested in exploring a possible transaction with CoLucid Pharmaceuticals, Inc. (the ?Company?) (such possible business relationship between you and the Comp

Offer To Purchase All Outstanding Shares of Common Stock COLUCID PHARMACEUTICALS, INC. $46.50 Per Share, Net in Cash PROCAR ACQUISITION CORPORATION, a wholly-owned subsidiary of ELI LILLY AND COMPANY

EX-99.(a)(1)(A) Table of Contents Exhibit (a)(1)(A) Offer To Purchase All Outstanding Shares of Common Stock of COLUCID PHARMACEUTICALS, INC. at $46.50 Per Share, Net in Cash by PROCAR ACQUISITION CORPORATION, a wholly-owned subsidiary of ELI LILLY AND COMPANY THE OFFER AND WITHDRAWAL RIGHTS WILL EXPIRE AT ONE MINUTE PAST 11:59 P.M., NEW YORK CITY TIME, ON FEBRUARY 28, 2017, UNLESS THE OFFER IS EX

LETTER OF TRANSMITTAL To Tender Shares of Common Stock COLUCID PHARMACEUTICALS, INC. $46.50 Per Share, Net in Cash Pursuant to the Offer to Purchase dated January 31, 2017 PROCAR ACQUISITION CORPORATION, a wholly-owned subsidiary ELI LILLY AND COMPAN

EX-99.(a)(1)(B) Exhibit (a)(1)(B) LETTER OF TRANSMITTAL To Tender Shares of Common Stock of COLUCID PHARMACEUTICALS, INC. at $46.50 Per Share, Net in Cash Pursuant to the Offer to Purchase dated January 31, 2017 by PROCAR ACQUISITION CORPORATION, a wholly-owned subsidiary of ELI LILLY AND COMPANY THE OFFER AND WITHDRAWAL RIGHTS WILL EXPIRE AT ONE MINUTE PAST 11:59 P.M., NEW YORK CITY TIME, ON TUES

NOTICE OF GUARANTEED DELIVERY To Tender Shares of Common Stock COLUCID PHARMACEUTICALS, INC. $46.50 PER SHARE, NET IN CASH Pursuant to the Offer to Purchase dated January 31, 2017 PROCAR ACQUISITION CORPORATION, a wholly-owned subsidiary ELI LILLY AN

EX-99.(a)(1)(C) Exhibit (a)(1)(C) NOTICE OF GUARANTEED DELIVERY To Tender Shares of Common Stock of COLUCID PHARMACEUTICALS, INC. at $46.50 PER SHARE, NET IN CASH Pursuant to the Offer to Purchase dated January 31, 2017 by PROCAR ACQUISITION CORPORATION, a wholly-owned subsidiary of ELI LILLY AND COMPANY THE OFFER AND WITHDRAWAL RIGHTS WILL EXPIRE AT ONE MINUTE PAST 11:59 P.M., NEW YORK CITY TIME,

Offer to Purchase All Outstanding Shares of Common Stock COLUCID PHARMACEUTICALS, INC. $46.50 PER SHARE, NET IN CASH Pursuant to the Offer to Purchase dated January 31, 2017 PROCAR ACQUISITION CORPORATION, a wholly-owned subsidiary ELI LILLY AND COMP

EX-99.(a)(1)(E) Exhibit (a)(1)(E) Offer to Purchase All Outstanding Shares of Common Stock of COLUCID PHARMACEUTICALS, INC. at $46.50 PER SHARE, NET IN CASH Pursuant to the Offer to Purchase dated January 31, 2017 by PROCAR ACQUISITION CORPORATION, a wholly-owned subsidiary of ELI LILLY AND COMPANY THE OFFER AND WITHDRAWAL RIGHTS WILL EXPIRE AT ONE MINUTE PAST 11:59 P.M., NEW YORK CITY TIME, ON TU

CLCD / CoLucid Pharmaceuticals, Inc. / LILLY ELI & CO - SC 13D Activist Investment

SC 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 CoLucid Pharmaceuticals, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 19716T101 (CUSIP Number) Copies to: Michael J. Harrington General Counsel Eli Lilly and Company Lilly Corporate Center Indianapolis, Indiana 46285

Joint Filing Agreement

EX-99.1 Exhibit 99.1 Joint Filing Agreement In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, the persons named below agree to the joint filing on behalf of each of them of a statement on Schedule 13D (including amendments thereto) with respect to the common stock, par value $0.001 per share, of CoLucid Pharmaceuticals, Inc., a Delaware corporation, and fur

CLCD / CoLucid Pharmaceuticals, Inc. / Care Capital III LLC - SC 13G Passive Investment

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2 (Amendment No. )* CoLucid Pharmaceuticals, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 19716T101 (CUSIP Number) December 31,

Lilly and CoLucid Pharmaceuticals Announce Agreement for Lilly To Acquire CoLucid $960 million deal will enhance Lilly’s existing pain management portfolio for migraine; adds potential near-term launch to its late-stage pipeline

EX-99.1 Exhibit 99.1 January 18, 2017 For Release: Immediately Refer to: Lauren Zierke; [email protected]; (317) 277-6524 (Media) Phil Johnson; [email protected]; (317) 655-6874 (Investors) Lilly and CoLucid Pharmaceuticals Announce Agreement for Lilly To Acquire CoLucid $960 million deal will enhance Lilly?s existing pain management portfolio for migraine; adds potential near-term lau

CoLucid Pharmaceuticals SC TO-C

SC TO-C UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 CoLucid Pharmaceuticals, Inc. (Name of Subject Company (Issuer)) ProCar Acquisition Corporation a wholly owned subsidiary of Eli Lilly and Company (Names of Filing Persons (Offerors)) Common Stock, $0.001 par va

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events

8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) January 17, 2017 COLUCID PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-37358 20-3419541 (State or other jurisdiction (Commission (IRS Em

TENDER AND SUPPORT AGREEMENT

EX-10.1 Exhibit 10.1 EXECUTION VERSION TENDER AND SUPPORT AGREEMENT This Tender and Support Agreement (this ?Agreement?) is made and entered into as of January 17, 2017, by and among Eli Lilly and Company, an Indiana corporation (?Parent?), ProCar Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of Parent (?Merger Sub?), and the Person listed as ?Stockholder? on the si

AGREEMENT AND PLAN OF MERGER ELI LILLY AND COMPANY PROCAR ACQUISITION CORPORATION (“Merger Sub”) COLUCID PHARMACEUTICALS, INC. (the “Company”) Dated as of January 17, 2017 TABLE OF CONTENTS Page ARTICLE 1 THE OFFER 2 Section 1.1 The Offer 2 Section 1

EX-2.1 Exhibit 2.1 EXECUTION VERSION AGREEMENT AND PLAN OF MERGER among ELI LILLY AND COMPANY (?Parent?), PROCAR ACQUISITION CORPORATION (?Merger Sub?) and COLUCID PHARMACEUTICALS, INC. (the ?Company?) Dated as of January 17, 2017 TABLE OF CONTENTS Page ARTICLE 1 THE OFFER 2 Section 1.1 The Offer 2 Section 1.2 Company Actions 5 ARTICLE 2 THE MERGER 6 Section 2.1 The Merger 6 Section 2.2 Merger Clo

Lilly and CoLucid Pharmaceuticals Announce Agreement for Lilly To Acquire CoLucid $960 million deal will enhance Lilly’s existing pain management portfolio for migraine; adds potential near-term launch to its late-stage pipeline

EX-99.1 Exhibit 99.1 January 18, 2017 Eli Lilly and Company Lilly Corporate Center Indianapolis, Indiana 46285 U.S.A. +1.317.276.2000 www.lilly.com For Release: Immediately Refer to: Lauren Zierke; [email protected]; (317) 277-6524 (Media) Phil Johnson; [email protected]; (317) 655-6874 (Investors) Lilly and CoLucid Pharmaceuticals Announce Agreement for Lilly To Acquire CoLucid $960 m

CoLucid Pharmaceuticals SC14D9C

SC14D9C UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 SOLICITATION/RECOMMENDATION STATEMENT UNDER SECTION 14(d)(4) OF THE SECURITIES EXCHANGE ACT OF 1934 COLUCID PHARMACEUTICALS, INC. (Name of Subject Company) COLUCID PHARMACEUTICALS, INC. (Name of Person(s) Filing Statement) Common Stock, par value $0.001 per share (Title of Class of Securities) 19716T 101

CLCD / CoLucid Pharmaceuticals, Inc. / Domain Partners VI, L.P. - SCHEDULE 13G/A FOR COLUCID PHARMACEUTICALS, INC. BY DOMAIN PARTNERS VI, L.P. Passive Investment

SC 13G/A 1 13ga010717-colucid.htm SCHEDULE 13G/A FOR COLUCID PHARMACEUTICALS, INC. BY DOMAIN PARTNERS VI, L.P. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b),(c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. 1)1 CoLucid Pharmaceuticals, Inc. (Name of Issu

Financial Statements and Exhibits, Results of Operations and Financial Condition

8-K 1 clcd-8k20161109.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 9, 2016 COLUCID PHARMACEUTICALS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37358 20-3419541 (State or Other

CoLucid Pharmaceuticals Announces 2016 Third Quarter Results and Corporate Highlights

EX-99 2 clcd-ex996.htm EX-99 Exhibit 99 CoLucid Pharmaceuticals Announces 2016 Third Quarter Results and Corporate Highlights CAMBRIDGE, MA – November 9, 2016 – CoLucid Pharmaceuticals, Inc. (NASDAQ: CLCD) today reported financial and operating results for the quarter ended September 30, 2016. Corporate Highlights In September 2016 CoLucid announced that it had completed its first pivotal Phase 3

CoLucid Pharmaceuticals FORM 10-Q (Quarterly Report)

clcd-10q20160930.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2016 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file nu

AMENDMENT to EMPLOYMENT AGREEMENT

EX-10.2 EXHIBIT 10.2 AMENDMENT to EMPLOYMENT AGREEMENT This Amendment (the ?Amendment?), dated October 6, 2016, amends that certain Employment Agreement (?Agreement?) made and entered into effective as of February 7, 2015 (?Effective Date?) by and between CoLucid Pharmaceuticals, Inc., a Delaware corporation (the ?Company?), and Matthew Dallas (?Executive?). Capitalized terms used herein and not o

AMENDMENT to EMPLOYMENT AGREEMENT

EX-10.1 EXHIBIT 10.1 AMENDMENT to EMPLOYMENT AGREEMENT This Amendment (the ?Amendment?), dated October 6, 2016, amends that certain Employment Agreement (?Agreement?) made and entered into effective as of January 13, 2015 (?Effective Date?) by and between CoLucid Pharmaceuticals, Inc., a Delaware corporation (the ?Company?), and Thomas P. Mathers (?Executive?). Capitalized terms used herein and no

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): October 6, 2016 COLUCID PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-37358 20-3419541 (State or other jurisdiction of incorporation or

CLCD / CoLucid Pharmaceuticals, Inc. / PRICE T ROWE ASSOCIATES INC /MD/ - CLCD AS OF 09/30/2016 Passive Investment

SC 13G/A 1 clcd13gasep16.htm CLCD AS OF 09/30/2016 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1) COLUCID PHARMACEUTICALS INC (Name of Issuer) COMMON STOCK (Title of Class of Securities) 19716T101 (CUSIP Number) September 30, 2016 (Date of Event which Requires Filing of Statement) Check the appropriat

CLCD / CoLucid Pharmaceuticals, Inc. / Novo A/S - SC 13D/A Activist Investment

SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1)* CoLucid Pharmaceuticals, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 19716T 101 (CUSIP Number) Thomas Dyrberg Novo A/S Tuborg Havnevej 19 Hellerup, Denmark DK-2900 +45 3527 6592 Copy to: B. Shayn

POWER OF ATTORNEY

EX-24.1 Exhibit 24.1 POWER OF ATTORNEY Novo A/S, a Denmark corporation, hereby grants Power of Attorney to Thomas Dyrberg, and appoints him as attorney-in-fact, to prepare, execute and submit in the name of and on behalf of Novo A/S, the following documents: Forms 3, 4, and 5, Schedules 13G and 13D, Forms 13F and 13H, and any amendments thereto, and any other filings advisable or required to be fi

Regulation FD Disclosure, Financial Statements and Exhibits, Other Events

Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): September 9, 2016 COLUCID PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-37358 20-3419541 (State or other jurisdiction of incorpora

3,250,000 Shares CoLucid Pharmaceuticals, Inc. Common Stock PURCHASE AGREEMENT

EX-1.1 Exhibit 1.1 3,250,000 Shares CoLucid Pharmaceuticals, Inc. Common Stock PURCHASE AGREEMENT September 9, 2016 PIPER JAFFRAY & CO. BARCLAYS CAPITAL INC. As Representatives of the several Underwriters named in Schedule I hereto c/o Piper Jaffray & Co. 800 Nicollet Mall Minneapolis, Minnesota 55402 c/o Barclays Capital Inc. 745 Seventh Avenue New York, New York 10019 Ladies and Gentlemen: CoLuc

CoLucid Pharmaceuticals Announces Pricing of Public Offering of Common Stock

EX-99.1 Exhibit 99.1 CoLucid Pharmaceuticals Announces Pricing of Public Offering of Common Stock Cambridge, MA, September 9, 2016 ? CoLucid Pharmaceuticals, Inc. (?CoLucid?) (Nasdaq: CLCD), a biopharmaceutical company that is developing lasmiditan oral tablets for the acute treatment of migraine in adults, today announced the pricing of an underwritten public offering of 3,250,000 shares of its c

The date of this prospectus supplement is September 9, 2016.

424B5 1 d250009d424b5.htm 424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-211865 Prospectus Supplement (To Prospectus dated June 24, 2016) 3,250,000 Shares COLUCID PHARMACEUTICALS, INC. Common Stock $20.00 per share We are offering 3,250,000 shares of our common stock. Our common stock is listed on The NASDAQ Global Market under the symbol “CLCD”. The last reported sa

Subject to completion, dated September 8, 2016

424B5 Table of Contents The information in this preliminary prospectus supplement and the accompanying prospectus, relating to an effective registration statement under the Securities Act of 1933, as amended, is not complete and may be changed.

Other Events

Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): September 8, 2016 COLUCID PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-37358 20-3419541 (State or other jurisdiction of incorpora

CoLucid Pharmaceuticals Announces 2016 Second Quarter Results and Corporate Highlights

clcd-ex996.htm Exhibit 99 CoLucid Pharmaceuticals Announces 2016 Second Quarter Results and Corporate Highlights CAMBRIDGE, MA ? August 10, 2016 ? CoLucid Pharmaceuticals, Inc. (NASDAQ: CLCD) today reported financial and operating results for the quarter ended June 30, 2016. Corporate Highlights On June 7, CoLucid announced that the last patient has been randomized in SAMURAI the first Phase 3 piv

CoLucid Pharmaceuticals Announces 2016 Second Quarter Results and Corporate Highlights

clcd-ex996.htm Exhibit 99 CoLucid Pharmaceuticals Announces 2016 Second Quarter Results and Corporate Highlights CAMBRIDGE, MA ? August 10, 2016 ? CoLucid Pharmaceuticals, Inc. (NASDAQ: CLCD) today reported financial and operating results for the quarter ended June 30, 2016. Corporate Highlights On June 7, CoLucid announced that the last patient has been randomized in SAMURAI the first Phase 3 piv

Financial Statements and Exhibits, Results of Operations and Financial Condition

8-K 1 clcd-8k20160810.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 10, 2016 COLUCID PHARMACEUTICALS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37358 20-3419541 (State or Other J

Financial Statements and Exhibits, Results of Operations and Financial Condition

8-K 1 clcd-8k20160810.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 10, 2016 COLUCID PHARMACEUTICALS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37358 20-3419541 (State or Other J

CoLucid Pharmaceuticals FORM 10-Q (Quarterly Report)

clcd-10q20160630.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2016 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number:

CoLucid Pharmaceuticals ESP

Acceleration request CoLucid Pharmaceuticals, Inc. 222 Third Street, Suite 1320 Cambridge, Massachusetts 02142 June 21, 2016 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F. Street, N.E. Washington, D.C. 20549 Re: CoLucid Pharmaceuticals, Inc. Registration Statement on Form S-3 File No. 333-211865 Ladies and Gentlemen: Pursuant to Rule 461 under the Securities Ac

CoLucid Pharmaceuticals AMENDMENT NO. 1 TO FORM S-3

Amendment No. 1 to Form S-3 Table of Contents As filed with the Securities and Exchange Commission on June 16, 2016. Registration No. 333-211865 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 1 to FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 COLUCID PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 20-34

CoLucid Pharmaceuticals ESP

Letter to the SEC Jonathan R. Zimmerman Partner [email protected] Direct +1 612 766 8419 Faegre Baker Daniels LLP 2200 Wells Fargo Center q 90 South Seventh Street Minneapolis q Minnesota 55402-3901 Main +1 612 766 7000 Fax +1 612 766 1600 Via EDGAR June 16, 2016 Suzanne Hayes Assistant Director Office of Healthcare and Insurance U.S. Securities and Exchange Commission 100 F Street, NE Wa

CoLucid Pharmaceuticals S-3

S-3 Table of Contents As filed with the Securities and Exchange Commission on June 6, 2016.

COLUCID PHARMACEUTICALS, INC. Dated as of , 20 TABLE OF CONTENTS Page ARTICLE I. DEFINITIONS AND INCORPORATION BY REFERENCE 1 Section 1.1. Definitions. 1 Section 1.2. Other Definitions. 3 Section 1.3. Incorporation by Reference of Trust Indenture Act

EX-4.6 Exhibit 4.6 COLUCID PHARMACEUTICALS, INC. INDENTURE Dated as of , 20 Trustee TABLE OF CONTENTS Page ARTICLE I. DEFINITIONS AND INCORPORATION BY REFERENCE 1 Section 1.1. Definitions. 1 Section 1.2. Other Definitions. 3 Section 1.3. Incorporation by Reference of Trust Indenture Act. 3 Section 1.4. Rules of Construction. 4 ARTICLE II. THE SECURITIES 4 Section 2.1. Issuable in Series. 4 Section

CoLucid Pharmaceuticals 10-Q (Quarterly Report)

10-Q 1 clcd-10q20160331.htm 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2016 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission

Financial Statements and Exhibits, Results of Operations and Financial Condition

8-K 1 clcd-8k20160511.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 11, 2016 COLUCID PHARMACEUTICALS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37358 20-3419541 (State or Other Jurisdict

CoLucid Pharmaceuticals Announces 2016 First Quarter Results and Corporate Highlights

clcd-ex996.htm Exhibit 99 CoLucid Pharmaceuticals Announces 2016 First Quarter Results and Corporate Highlights CAMBRIDGE, MA ? May 11, 2016 ? CoLucid Pharmaceuticals, Inc. (NASDAQ: CLCD) today reported financial and operating results for the first quarter ended March 31, 2016. Corporate Highlights During the first quarter of 2016, CoLucid continued to randomize migraine patients for SAMURAI, its

Submission of Matters to a Vote of Security Holders

8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 10, 2016 COLUCID PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-37358 20-3419541 (State or other jurisdiction of (Commission (I.R.S.

COLUCID PHARMACEUTICALS, INC. 2015 EQUITY INCENTIVE PLAN Restricted Stock Unit Award Agreement

Exhibit 10.1 COLUCID PHARMACEUTICALS, INC. 2015 EQUITY INCENTIVE PLAN Restricted Stock Unit Award Agreement CoLucid Pharmaceuticals, Inc. (the “Company”), pursuant to its 2015 Equity Incentive Plan (the “Plan”), hereby grants an award of Restricted Stock Units to you, the Participant named below. The terms and conditions of this Award are set forth in this Restricted Stock Unit Award Agreement (th

CoLucid Pharmaceuticals DEFA14A

DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, For Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy Statement x Definitive Additional Materials ? Soliciting Material Pursuant to Section 240.

CoLucid Pharmaceuticals DEF 14A

DEF 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.

CoLucid Pharmaceuticals S-8

S-8 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 COLUCID PHARMACEUTICALS, INC.

C ONS U L T I N G A GRE E M E N T

Exhibit 10.12 Execution Version C ONS U L T I N G A GRE E M E N T This Consulting Agreement (this “Agreement”) is entered into as of January 20, 2016, between CoLucid Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and Nadia Rupniak (“Rupniak”); provided, however, that this Agreement shall become binding and effective only in accordance with, and subject to, Section 6(i) below. Reci

*********************

Exhibit 10.14 November 7, 2015 Raymond Skwierczynski, Ph.D. (address redacted) Dear Ray: Pursuant to our recent discussions, I would like to offer you employment with CoLucid Pharmaceuticals, Inc. (“CoLucid” or the “Company”). The terms of your employment are set forth in this employment letter and will be accompanied by a separate Confidentiality, Inventions and Non-Competition Agreement between

CoLucid Pharmaceuticals 10-K (Annual Report)

clcd-10k20151231.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2015 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-

CoLucid Pharmaceuticals Announces Election of Alison Lawton to Board of Directors

EX-99.1 Exhibit 99.1 CoLucid Pharmaceuticals Announces Election of Alison Lawton to Board of Directors CAMBRIDGE, MA, March 15, 2016 ? CoLucid Pharmaceuticals, Inc. (NASDAQ: CLCD), a Phase 3 clinical-stage biopharmaceutical company that is developing its lead product candidate, lasmiditan, for the acute treatment of migraine headaches in adults, announced today that Alison Lawton, has been elected

CoLucid Pharmaceuticals 8-K (Current Report/Significant Event)

8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 11, 2016 COLUCID PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-37358 20-3419541 (State or other jurisdiction of incorporation or

EX-24

POWER OF ATTORNEY For Executing Forms 144, Forms 3, 4, 5 and Form ID The undersigned hereby constitutes and appoints Daniel L.

CoLucid Pharmaceuticals 8-K (Current Report/Significant Event)

clcd-8k20160302.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 2, 2016 COLUCID PHARMACEUTICALS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37358 20-3419541 (State or Other Jurisdiction of In

CoLucid Pharmaceuticals Announces 2015 Fourth Quarter and Year-End Results and Corporate Highlights

clcd-ex996.htm Exhibit 99 CoLucid Pharmaceuticals Announces 2015 Fourth Quarter and Year-End Results and Corporate Highlights CAMBRIDGE, MA ? March 2, 2016 ? CoLucid Pharmaceuticals, Inc. (NASDAQ: CLCD) today reported financial and operating results for the fourth quarter and year ended December 31, 2015. Corporate Highlights During the fourth quarter, CoLucid announced that it had randomized over

JOINT FILING AGREEMENT

EX-99.4 Exhibit 4 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, the undersigned agree to the joint filing on behalf of each of them of a statement on Schedule 13D (including amendments thereto) with respect to the Common Stock, par value $0.001, of CoLucid Pharmaceuticals, Inc. and further agree that this agreement be included as an

CLCD / CoLucid Pharmaceuticals, Inc. / PAPPAS CAPITAL, LLC - SC 13D/A Activist Investment

SC 13D/A SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13D/A (Amendment No.

CLCD / CoLucid Pharmaceuticals, Inc. / PAPPAS CAPITAL, LLC - SC 13D Activist Investment

SC 13D SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.

JOINT FILING AGREEMENT

EX-99.4 Exhibit 4 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, the undersigned agree to the joint filing on behalf of each of them of a statement on Schedule 13D (including amendments thereto) with respect to the Common Stock, par value $0.001, of CoLucid Pharmaceuticals, Inc. and further agree that this agreement be included as an

CLCD / CoLucid Pharmaceuticals, Inc. / PRICE T ROWE ASSOCIATES INC /MD/ - CLCD AS OF 12/31/2015 Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. ) COLUCID PHARMACEUTICALS INC (Name of Issuer) COMMON STOCK (Title of Class of Securities) 19716T101 (CUSIP Number) December 31, 2015 (Date of Event which Requires Filing of Statement) Check the appropriate box to designate the Rule pursuant to which this Sc

CLCD / CoLucid Pharmaceuticals, Inc. / Domain Partners VI, L.P. - SCHEDULE 13G FOR COLUCID PHARMACEUTICALS, INC. BY DOMAIN PARTNERS VI, L.P. Passive Investment

CUSIP No. 19716T101 Page 1 of 8 Pages SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b),(c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. )1 CoLucid Pharmaceuticals, Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 19716T10

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): December 29, 2015 COLUCID PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-37358 20-3419541 (State or other jurisdiction of incorpora

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

8-K 1 d105326d8k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): December 11, 2015 COLUCID PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-37358 20-3419541 (State or other juri

EX-24

POWER OF ATTORNEY For Executing Forms 144, Forms 3, 4, 5 and Form ID The undersigned hereby constitutes and appoints Daniel L.

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 10, 2015 COLUCID PHARMACEUTICALS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37358 20-3419541 (State or Other Jurisdiction of Incorporation) (Co

CoLucid Pharmaceuticals Announces Third Quarter 2015 Results and Corporate Highlights

clcd-ex996.htm Exhibit 99 CoLucid Pharmaceuticals Announces Third Quarter 2015 Results and Corporate Highlights CAMBRIDGE, MA ? November 10, 2015 ? CoLucid Pharmaceuticals, Inc. (NASDAQ: CLCD) today reported financial and operating results for the third quarter ended September 30, 2015. Corporate Highlights CoLucid continues to enroll patients in SAMURAI, its first of two pivotal Phase 3 clinical

EX-24

POWER OF ATTORNEY For Executing Forms 144, Forms 3, 4, 5 and Form ID The undersigned hereby constitutes and appoints Daniel L.

CoLucid Pharmaceuticals Announces Election of Mark Corrigan, M.D., to Board of Directors

EX-99 Exhibit 99 CoLucid Pharmaceuticals Announces Election of Mark Corrigan, M.D., to Board of Directors CAMBRIDGE, MA, October 27, 2015 ? CoLucid Pharmaceuticals, Inc. (NASDAQ: CLCD), a Phase 3 clinical-stage biopharmaceutical company that is developing its lead product candidate, lasmiditan, for the acute treatment of migraine headaches in adults, announced today that Mark Corrigan M.D., has be

CoLucid Pharmaceuticals FORM 8-K (Current Report/Significant Event)

Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): October 27, 2015 COLUCID PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-37358 20-3419541 (State or other jurisdiction (Commission (

CoLucid Pharmaceuticals Announces Second Quarter 2015 Results and Corporate Highlights

EX-99 Exhibit 99 CoLucid Pharmaceuticals Announces Second Quarter 2015 Results and Corporate Highlights ? Enrolled the first patient in the SAMURAI trial, the first of two phase 3 pivotal clinical trials investigating lasmiditan for the acute treatment of migraine headaches ? Priced its initial public offering of 5,500,000 shares of common stock at a public offering price of $10.

Financial Statements and Exhibits, Results of Operations and Financial Condition

Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 12, 2015 COLUCID PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-37358 20-3419541 (State or other jurisdiction of incorporati

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

8-K 1 d51981d8k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 4, 2015 COLUCID PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-37358 20-3419541 (State or other jurisdic

CoLucid Pharmaceuticals FORM 8-K (Current Report/Significant Event)

Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 9, 2015 COLUCID PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-37358 20-3419541 (State or other jurisdiction of (Commission (I

CoLucid Pharmaceuticals Announces Appointment of Marvin L. White to Board of Directors

EX-99 Exhibit 99 CoLucid Pharmaceuticals Announces Appointment of Marvin L. White to Board of Directors CAMBRIDGE, Massachusetts, July 13, 2015 ? CoLucid Pharmaceuticals, Inc. (Nasdaq: CLCD), a Phase 3 clinical-stage biopharmaceutical company that is developing its lead product candidate, lasmiditan, for the acute treatment of migraine headaches, announced today the appointment of Marvin L. White

EX-24

POWER OF ATTORNEY For Executing Forms 144, Forms 3, 4, 5 and Form ID The undersigned hereby constitutes and appoints Daniel L.

CLCD / CoLucid Pharmaceuticals, Inc. / Novo A/S - SC 13D Activist Investment

SC 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. )* CoLucid Pharmaceuticals, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 19716T 101 (CUSIP Number) Bjarne Graven Larsen Novo A/S Tuborg Havnevej 19 Hellerup, Denmark DK-2900 +45 3527 6592 Copy to: B. Sh

Form of Lock-Up Agreement

EX-99.B Exhibit B Form of Lock-Up Agreement [Date], 2015 Piper Jaffray & Co. Stifel Nicolaus & Company, Incorporated As representatives of the underwriters named in Schedule II to the Purchase Agreement referred to below c/o Piper Jaffray & Co. 800 Nicollet Mall, Suite 800 Minneapolis, MN 55402 c/o Stifel, Nicolaus & Company, Incorporated One Montgomery Street, Suite 3700 San Francisco, CA 94104 D

COLUCID PHARMACEUTICALS, INC. AMENDED AND RESTATED BY-LAWS Effective: May 11, 2015 ARTICLE I

Exhibit 3.2 Exhibit 3.2 COLUCID PHARMACEUTICALS, INC. AMENDED AND RESTATED BY-LAWS Effective: May 11, 2015 ARTICLE I OFFICES Section 1.1 REGISTERED OFFICE. The Corporation shall maintain a registered office and registered agent within the State of Delaware at such place within such State as may be designated from time to time by the Board of Directors of the Corporation. Section 1.2 OTHER OFFICES.

FIFTH AMENDED AND RESTATED CERTIFICATE OF INCORPORATION COLUCID PHARMACEUTICALS, INC.

Exhibit 3.1 Exhibit 3.1 FIFTH AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF COLUCID PHARMACEUTICALS, INC. CoLucid Pharmaceuticals, Inc., a corporation organized and existing under the laws of the State of Delaware, hereby certifies as follows: A. The name of the corporation is CoLucid Pharmaceuticals, Inc. The Corporation?s original Certificate of Incorporation was filed with the Secretary

CoLucid Pharmaceuticals FORM 8-K (Current Report/Significant Event)

Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 11, 2015 COLUCID PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-37358 20-3419541 (State or other jurisdiction of incorporation

The date of this prospectus is May 5, 2015.

424B4 Table of Contents Filed Pursuant to Rule 424(b)4 Registration No. 333-203100 5,500,000 Shares COLUCID PHARMACEUTICALS, INC. Common Stock $10.00 per share ? CoLucid Pharmaceuticals, Inc. is offering 5,500,000 shares. ? The initial public offering price is $10.00 per share. ? This is our initial public offering and no public market currently exists for our shares. ? Our common stock has been a

EX-24

POWER OF ATTORNEY For Executing Forms 144, Forms 3, 4, 5 and Form ID The undersigned hereby constitutes and appoints Daniel L.

EX-24

CARE CAPITAL III LLC CARE CAPITAL INVESTMENTS III, LP CARE CAPITAL OFFSHORE INVESTMENTS III, LP POWER OF ATTORNEY For Executing Forms 144, Forms 3, 4, 5 and Form ID Each of the undersigned, including (i) Care Capital III LLC; (ii) Care Capital Investments III, LP; and (iii) Care Capital Offshore Investments III, LP hereby and appoints Daniel L.

EX-24

POWER OF ATTORNEY For Executing Forms 144, Forms 3, 4, 5 and Form ID The undersigned hereby constitutes and appoints Daniel L.

CoLucid Pharmaceuticals FORM S-8

Form S-8 As filed with the Securities and Exchange Commission on May 5, 2015 Registration Number 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 COLUCID PHARMACEUTICALS, INC.

EX-24

POWER OF ATTORNEY For Executing Forms 144, Forms 3, 4, 5 and Form ID The undersigned hereby constitutes and appoints Daniel L.

CoLucid Pharmaceuticals AMENDMENT NO. 6 TO FORM S-1

Amendment No. 6 to Form S-1 Table of Contents As filed with the Securities and Exchange Commission on May 5, 2015. Registration No. 333-203100 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 6 TO FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 COLUCID PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 2834 20

EX-24

POWER OF ATTORNEY For Executing Forms 144, Forms 3, 4, 5 and Form ID The undersigned hereby constitutes and appoints Daniel L.

COLUCID PHARMACEUTICALS, INC. FREE WRITING PROSPECTUS

FWP Filed Pursuant to Rule 433 of the Securities Act of 1933 Issuer Free Writing Prospectus dated May 5, 2015 Relating to Preliminary Prospectus dated April 20, 2015 Registration No.

EX-24

POWER OF ATTORNEY For Executing Forms 144, Forms 3, 4, 5 and Form ID The undersigned hereby constitutes and appoints Daniel L.

CoLucid Pharmaceuticals ESP

Company acceleration request CoLucid Pharmaceuticals, Inc. 15 New England Executive Park Burlington, Massachusetts 01803 May 5, 2015 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F. Street, N.E. Washington, D.C. 20549 Re: CoLucid Pharmaceuticals, Inc. Registration Statement on Form S-1 File No. 333-203100 Acceleration Request Requested Date: May 5, 2015 Requested

EX-24

POWER OF ATTORNEY For Executing Forms 144, Forms 3, 4, 5 and Form ID The undersigned hereby constitutes and appoints Daniel L.

EX-24

POWER OF ATTORNEY For Executing Forms 144, Forms 3, 4, 5 and Form ID The undersigned hereby constitutes and appoints Daniel L.

EX-24

POWER OF ATTORNEY For Executing Forms 144, Forms 3, 4, 5 and Form ID The undersigned hereby constitutes and appoints Daniel L.

EX-24

POWER OF ATTORNEY For Executing Forms 144, Forms 3, 4, 5 and Form ID The undersigned hereby constitutes and appoints Daniel L.

EX-24

A.M. PAPPAS LIFE SCIENCE VENTURES III, L.P. PV III CEO FUND, L.P. A.M. PAPPAS & ASSOCIATES, LLC POWER OF ATTORNEY For Executing Forms 144, Forms 3, 4, 5 and Form ID Each of the undersigned, including (i) A.M. Pappas Life Science Ventures III, L.P.; (ii) PV III CEO Fund, L.P.; and (iii) A.M. Pappas & Associates, LLC hereby constitutes and appoints Daniel L. Boeglin, Christine G. Long, Jonathan R. Z

EX-24

POWER OF ATTORNEY For Executing Forms 144, Forms 3, 4, 5 and Form ID The undersigned hereby constitutes and appoints Daniel L.

CoLucid Pharmaceuticals ESP

Underwriter Acceleration Request May 5, 2015 Securities and Exchange Commission 100 F Street, N.

CoLucid Pharmaceuticals S-1/A

S-1/A Table of Contents As filed with the Securities and Exchange Commission on April 30, 2015.

COLUCID PHARMACEUTICALS, INC. FREE WRITING PROSPECTUS

FWP 1 d876348dfwp.htm FWP Filed Pursuant to Rule 433 of the Securities Act of 1933 Issuer Free Writing Prospectus dated April 28, 2015 Relating to Preliminary Prospectus dated April 20, 2015 Registration No. 333-203100 COLUCID PHARMACEUTICALS, INC. FREE WRITING PROSPECTUS This free writing prospectus relates only to, and should be read together with, the preliminary prospectus dated April 20, 2015

CoLucid Pharmaceuticals AMENDMENT NO.4 TO FORM S-1

Amendment No.4 to Form S-1 Table of Contents As filed with the Securities and Exchange Commission on April 28, 2015. Registration No. 333-203100 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 4 TO FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 COLUCID PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 2834

CoLucid Pharmaceuticals FORM 8-A12B

Form 8-A12B UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-A FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 COLUCID PHARMACEUTICALS, INC.

CoLucid Pharmaceuticals ESP

Company Acceleration request CoLucid Pharmaceuticals, Inc. 15 New England Executive Park Burlington, Massachusetts 01803 April 27, 2015 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F. Street, N.E. Washington, D.C. 20549 Re: CoLucid Pharmaceuticals, Inc. Registration Statement on Form S-1 File No. 333-203100 Acceleration Request Requested Date: April 29, 2015 Req

CoLucid Pharmaceuticals ESP

Underwriter Acceleration Request April 27, 2015 Securities and Exchange Commission 100 F Street, N.

CoLucid Pharmaceuticals S-1/A

S-1/A Table of Contents As filed with the Securities and Exchange Commission on April 23, 2015.

CoLucid Pharmaceuticals ESP

Jonathan R. Zimmerman Partner [email protected] Direct +1 612 766 8419 Faegre Baker Daniels LLP 2200 Wells Fargo Center ? 90 South Seventh Street Minneapolis ? Minnesota 55402-3901 Phone +1 612 766 7000 Fax +1 612 766 1600 By EDGAR and Federal Express April 23, 2015 Jeffrey P. Riedler Assistant Director U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street,

CoLucid Pharmaceuticals S-1/A AMENDMENT #2

S-1/A Amendment #2 Table of Contents As filed with the Securities and Exchange Commission on April 20, 2015.

CoLucid Pharmaceuticals ESP

SEC letter Jonathan R. Zimmerman Partner [email protected] Direct +1 612 766 8419 Faegre Baker Daniels LLP 2200 Wells Fargo Center, 90 South Seventh Street Minneapolis, Minnesota 55402-3901 Phone +1 612 766 7000 Fax +1 612 766 1600 By EDGAR April 17, 2015 Lisa Vanjoske Assistant Chief Accountant U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, NE Washi

CoLucid Pharmaceuticals ESP

SEC Comment Letter Jonathan R. Zimmerman Partner [email protected] Direct +1 612 766 8419 Faegre Baker Daniels LLP 2200 Wells Fargo Center, 90 South Seventh Street Minneapolis, Minnesota 55402-3901 Phone +1 612 766 7000 Fax +1 612 766 1600 By EDGAR April 14, 2015 Lisa Vanjoske Assistant Chief Accountant U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street,

CoLucid Pharmaceuticals AMENDMENT NO. 1 TO FORM S-1

Amendment No. 1 to Form S-1 Table of Contents As filed with the Securities and Exchange Commission on April 10, 2015. Registration No. 333-203100 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 1 TO FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 COLUCID PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 2834

CoLucid Pharmaceuticals ESP

Jonathan R. Zimmerman Partner [email protected] Direct +1 612 766 8419 Faegre Baker Daniels LLP 2200 Wells Fargo Center, 90 South Seventh Street Minneapolis, Minnesota 55402-3901 Phone +1 612 766 7000 Fax +1 612 766 1600 By EDGAR and Federal Express April 10, 2015 Jeffrey P. Riedler Assistant Director U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, NE

CoLucid Pharmaceuticals ESP

Response Letter Jonathan R. Zimmerman Partner [email protected] Direct +1 612 766 8419 Faegre Baker Daniels LLP 2200 Wells Fargo Center q 90 South Seventh Street Minneapolis q Minnesota 55402-3901 Phone +1 612 766 7000 Fax +1 612 766 1600 By EDGAR and Federal Express March 30, 2015 Jeffrey P. Riedler Assistant Director U.S. Securities and Exchange Commission Division of Corporation Financ

CLCD / CoLucid Pharmaceuticals, Inc. DRS - -

DRS Table of Contents As submitted to the Securities and Exchange Commission confidentially on February 24, 2015 As filed with the Securities and Exchange Commission on , 2015.